BENJAMIN LITTENBERG, MD
Osteopathic Medicine at Prospect St, Burlington, VT

License number

Vermont 042-0009929

Personal information

See more information about BENJAMIN LITTENBERG at radaris.com

Name

Address

Phone

Benjamin Littenberg

101 Ledge Rd, Burlington, VT 05401

(802) 859-0287

Benjamin A Littenberg, age 67

101 Ledge Rd, Burlington, VT 05401

(802) 859-0287

Benjamin A Littenberg, age 67

101 Ledge Rd, Burlington, VT 05401

(802) 859-0287

Benjamin A Littenberg, age 67

1 Ledge Rd, Burlington, VT 05401

(802) 859-0287

Benjamin A Littenberg, age 67

1 Ledge Rd, Burlington, VT 05401

(802) 859-0287

Professional information

Professor At University Of Vermont And Chief Medical Officer At Patient Engagement Systems

Position:

Chief Medical Officer at Patient Engagement Systems, Professor at University of Vermont, NYC A1C Registry Advisory Board Member at New York City Department of Health, Board of Review Member at GERRAF, Attending Physician at Fletcher Allen Health Care

Location:

Burlington, Vermont

Industry:

Hospital & Health Care

Work:

Patient Engagement Systems since Jul 2010 - Chief Medical Officer University of Vermont since Apr 1999 - Professor New York City Department of Health since 2006 - NYC A1C Registry Advisory Board Member GERRAF since 2000 - Board of Review Member Fletcher Allen Health Care since Apr 1999 - Attending Physician Vermedx, Inc. Mar 2006 - Jun 2010 - Chief Executive Officer Washington University at St. Louis Jul 1994 - Apr 1999 - Director, General Internal Medicine Dartmouth College 1989 - 1994 - Assistant Professor of Medicine Stanford University School of Medicine 1986 - 1989 - Robert Wood Johnson Clinical Scholar

Education:

Stanford University School of Medicine 1986 - 1989
Case Western Reserve University School of Medicine 1979 - 1983
MD, Medicine Case Western Reserve University 1975 - 1979
BA, Economics

Skills:

Healthcare, Epidemiology, Healthcare Information Technology, EMR, EHR, Healthcare Management, Informatics, Hospitals, Clinical Research, Healthcare Consulting, Medicine, Public Health, Internal Medicine, Outcomes Research, Comparative Effectiveness, Strategy, Nursing, HIPAA, Quality Improvement, Orthopedic, Health Services Research, Clinical Trials, Health Policy, Leadership, Lifesciences, Medical Education, Diabetes, Data Analysis, Radiology, Disease Management, Health Information Exchange

Interests:

Chronic Disease Management, Health Care Information Exchange, Clinical Decision Support

Honor & Awards:

Fellow of the American College of Physicians University of Vermont University Scholar 2008-2009

Benjamin E Littenberg, Burlington VT

Specialties:

Allergy & Immunology, General Practice, Internal Medicine

Work:

Fletcher Allen Health Care
1 S Prospect St, Burlington, VT 05401

Education:

Case Western Reserve University(1983)

Benjamin Littenberg, Burlington VT

Specialties:

Internist

Address:

1 S Prospect St, Burlington, VT 05401
111 Colchester Ave, Burlington, VT 05401

Education:

Case Western Reserve University, School of Medicine - Doctor of Medicine

Board certifications:

American Board of Internal Medicine Certification in Internal Medicine

Dr. Benjamin E Littenberg, Burlington VT - MD (Doctor of Medicine)

Specialties:

Internal Medicine

Address:

Burlington Given Health Cr Ctr
1 S Prospect St, Burlington 05401
(802) 847-4531 (Phone)

Certifications:

Internal Medicine, 1986

Awards:

Healthgrades Honor Roll

Languages:

English

Education:

Medical School
Case Western Reserve University School of Medicine
Graduated: 1983
Hartford Hospital
Stanford U/Rw Johnson Clin

Ribonuclease And Thiazolidinedione Compounds And Their Use In Methods To Treat Cancer

US Patent:

2009020, Aug 13, 2009

Filed:

Jan 6, 2009

Appl. No.:

12/349319

Inventors:

Benjamin Littenberg - Burlington VT, US

Assignee:

The University of Vermont and State Agriculture College - Burlington VT

International Classification:

A61K 38/46, A61P 35/00, C12N 9/22, C12Q 1/34

US Classification:

424 946, 435199, 435 18

Abstract:

The present invention relates to methods and kits for the treatment of cancer. A novel drug combination comprising a ribonuclease compound and a thiazolidinedione compound has been identified as producing a synergistic cytotoxicity effect in cancer cells. Methods and kits pertaining to the co-administration of these compounds are discussed herein.